Several years later (in 2006 and 2011), these two organisms also authorized the employment of this recombinant antibody as adjuvant therapy for patients with HER2+ early breast cancer (EBC) and, finally, in 2015 Tmab was added to the Essential Medicines List of the World Health Organization (WHO) [27]. The gene discussed is ERBB2; the disease is breast carcinoma.